Changes in rheology and red blood cell function under recombinant human erythropoietin therapy.
作者信息
Schmidt R, Lerche D, Dörp E, Winkler R, Klinkmann H
机构信息
Department of Internal Medicine, University of Rostock, FRG.
出版信息
Pol Arch Med Wewn. 1991 Jun;85(6):384-90.
PMID:1896402
Abstract
The rh-EPO is a potent drug to treat renal anaemia. RBC aggregation is not influenced by the rh-EPO therapy. Membrane elasticity and RBC deformability improve remarkably after rh-EPO which might benefit microcirculation. Rh-EPO therapy can not prolong RBC life span. Obviously uremic milieu alone determines RBC life time. Rh-EPO treatment corrects renal anemia by increasing the number of RBC and the RBC volume.
摘要
Zotero 插件